The aim of this study was to investigate whether and to what extent ou
r regime of cross-gender hormone replacement therapy might influence o
steoporosis development in transsexual patients. We found that after l
ong-term therapy the bone densities of our cross-gender hormone-treate
d transsexual groups (10 male-to-female and 10 female-to-male) did not
show significant differences compared to those of the corresponding b
iological sex. Moreover, the bone-density during therapy pointed out v
ery little variability and that independent of the gender-alteration (
transsexuality-direction) and the age of the transsexuals. Our results
indicate that for transsexual patients treated with cross-gender horm
one replacement therapy the risk of developing osteoporosis is low.